🔍 Observations
Topline
- Revenue from operations grew 12.4% YoY (₹5,583 Cr → ₹6,274 Cr in FY26), with Q4FY26 accelerating to 15.1% YoY (₹1,452 Cr → ₹1,670 Cr) — momentum is building into year-end.
- Performance & Other Chemicals dominates at 73.5% of FY26 segment revenue (₹4,609 Cr), growing 13.6% YoY; Life Science Chemicals contributed ₹1,805 Cr (+6.7% YoY) — both segments in sustained expansion.
- Q4FY26 inter-segment revenue fell to ₹52 Cr from ₹64 Cr in Q4FY25, indicating less internal cross-charging and cleaner external revenue quality.
Bottomline
- PAT attributable to owners surged 40.1% YoY (₹484 Cr → ₹678 Cr in FY26); Q4FY26 PAT jumped 66.2% YoY (₹127 Cr → ₹210 Cr) — the most decisive quarterly beat of the year.
- Basic EPS expanded from ₹164.37 to ₹230.25 (+40.1% YoY), with no dilution — all earnings growth is owner-accruing.
- A deferred tax charge of ₹39.6 Cr in FY26 (vs. ₹35.5 Cr in FY25) signals continued capex-linked timing differences; despite this, effective tax rate declined to 23.4% from 27.9%, partly aided by ₹14.2 Cr prior-year tax write-back in Q4.
Margins
- EBITDA (PBT + Finance costs + D&A, ex-other income): FY26 = ₹900.5 − ₹202.9 + ₹17.4 + ₹322.1 = ₹1,037.1 Cr on revenue of ₹6,273.5 Cr → EBITDA margin of 16.5% vs. FY25: (₹692.5 − ₹109 + ₹24 + ₹316.8) = ₹924.3 Cr / ₹5,583.4 Cr = 16.6% — broadly stable.
- Net profit margin (PAT attributable / Revenue): FY26 = ₹677.9 / ₹6,273.5 = 10.8% vs. FY25 = ₹483.9 / ₹5,583.4 = 8.7% — 210 bps expansion, a material quality improvement.
- Power & fuel costs declined as a share of revenue (FY26: 10.3% vs. FY25: 11.7%), while material costs held at 51.9% — input efficiency is improving on the energy side.
Growth Trajectory
- Revenue CAGR implied over FY25–FY26 is 12.4%; at Q4FY26 run-rate (₹1,670 Cr/quarter × 4 = ~₹6,680 Cr annualised), FY27 growth is tracking above trend.
- Segment EBIT margin for Life Science Chemicals: FY26 = ₹417 Cr / ₹1,805 Cr = 23.1% vs. FY25 = ₹347 Cr / ₹1,692 Cr = 20.5% — 260 bps expansion; Performance Chemicals: 9.0% vs. 8.5% — incremental but consistent.
- Other income nearly doubled YoY (₹109 Cr → ₹203 Cr), partly from investment gains (₹77 Cr FVTPL gains), suggesting the investment corpus is growing as a structural earnings contributor.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- PAT up 40% YoY with net margin expanding 210 bps — profit growth is outpacing revenue growth, confirming operating leverage is kicking in.
- Operating CFO of ₹1,023 Cr vs. ₹603 Cr prior year (+69.6% YoY) — earnings quality is high; cash conversion has sharply improved.
- Free cash flow positive: CFO ₹1,023 Cr less capex ₹175 Cr = FCF of ~₹848 Cr — company is strongly self-funding and capital-light relative to earnings.
- Life Science Chemicals EBIT margin at 23.1% — highest-margin segment expanding faster than revenue implies portfolio mix is upgrading.
- Debt reduction continues: Total borrowings fell from ₹197.7 Cr (FY25) to ₹179.8 Cr (FY26); net cash position (investments ₹1,648 Cr + cash ₹85 Cr − debt ₹180 Cr) is comfortably positive.
- Current investments nearly doubled (₹816 Cr → ₹1,648 Cr) — surplus capital is being deployed productively, not sitting idle.
- Power cost efficiency improved YoY as a revenue percentage, indicating energy intensity reduction amid volume growth.
🔴 Red Flags
- Trade receivables up 12.8% YoY (₹1,126 Cr → ₹1,271 Cr), growing in line with revenue — no deterioration, but receivables days remain elevated for a specialty chemicals business.
- MSME payables more than doubled (₹38 Cr → ₹89 Cr) — rising concentration in MSME creditors increases regulatory and reputational risk under MSME payment norms.
- Deferred tax liability rose sharply (₹225 Cr → ₹278 Cr, +₹53 Cr) — future cash tax outflows will normalise upward as timing differences reverse.
- Other income inflated by non-recurring items: ₹77 Cr in investment gains and ₹15.5 Cr in government grants boosted PBT — strip these out and recurring PBT growth is more modest.
- Capex declined meaningfully (₹270 Cr in FY25 → ₹175 Cr in FY26) — while FCF-accretive near-term, sustained undercapitalisation risks future capacity constraints in a growth cycle.
- Inventory build (+₹86 Cr YoY to ₹815 Cr) against revenue growth of 12.4% suggests inventory days are inching up — worth monitoring for demand softness.
📊 Balance Sheet Analysis
- Equity-heavy capital structure: Total equity at ₹6,297 Cr vs. total debt of ₹180 Cr — D/E is effectively negligible (<0.03x), giving the company substantial headroom for inorganic growth or capex acceleration.
- Asset quality is clean: PPE declined from ₹2,792 Cr to ₹2,619 Cr as depreciation outpaced fresh capex (₹322 Cr D&A vs. ₹175 Cr capex) — net block is gradually shrinking, which warrants monitoring if growth capex doesn’t recover.
- Liquidity is strong: Current ratio = ₹4,056 Cr / ₹1,122 Cr = 3.6x — comfortable; liquid investments of ₹1,648 Cr provide a substantial buffer.
- Working capital: net current assets = ₹4,056 Cr − ₹1,122 Cr = ₹2,934 Cr (FY26) vs. ₹2,061 Cr (FY25) — expansion driven by investment corpus growth, not operating stress.
💰 Cash Flow Analysis
- CFO conversion is exceptional: Operating profit before working capital changes = ₹1,098 Cr; after working capital and taxes, CFO = ₹1,023 Cr — ~93% conversion of pre-WC operating profit, implying tight operational discipline.
- Working capital was a net source of cash (₹248 Cr liability increase > ₹175 Cr asset increase) — suppliers are effectively funding the business cycle, a sign of pricing power and creditor confidence.
- Investing outflows dominated by financial investments (₹795 Cr net purchase of FVTPL current investments) rather than productive capex (₹175 Cr) — capital allocation is increasingly oriented toward treasury management over business reinvestment.
- Financing is clean: Dividends paid ₹73.6 Cr, debt repaid net, interest paid ₹17 Cr — no equity dilution, no aggressive leverage; the balance sheet is being conserved.
💡 Investment Outlook
Atul Ltd delivered a high-quality FY26, with PAT growth of 40% YoY driven by genuine operating leverage, margin expansion in both segments, and a near-tripling of operating cash flows — all on a debt-free-in-effect balance sheet.
The Life Science Chemicals segment’s margin trajectory (23.1% EBIT) and the growing investment corpus signal durable profitability ahead.
Key risks to monitor are the deceleration in productive capex, rising MSME payable exposure, and the dependence of reported PBT on non-recurring investment gains.
At current earnings momentum, the business is self-funding growth, but investors should watch whether FY27 capex reverts to fund the next leg of expansion.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial spreadsheets, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.